ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment Response - Top-Institutions - MDSpire

ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment Response

  • By

  • Julien Kirchgesner

  • Bram Verstockt

  • Michel Adamina

  • Kristine H Allin

  • Mariangela Allocca

  • Arno R Bourgonje

  • Johan Burisch

  • Glen Doherty

  • Parambir S Dulai

  • Alaa El-Hussuna

  • Ravi Misra

  • Nurulamin Noor

  • Valérie Pittet

  • Nick Powell

  • Iago Rodríguez-Lago

  • Sophie Restellini

  • May 4, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mount Sinai Hospital
    Mount Sinai Hospital

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Epidemiology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Translational Medicine

  • #3

    University of Cambridge
    University of Cambridge

    Cambridge, England

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Computational Biology

  • #4

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Research

  • #5

    University of Toronto
    University of Toronto

    Toronto, Ontario

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Epidemiology

Original Source(s)

ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment Response

  • by Julien Kirchgesner, Bram Verstockt, Michel Adamina, Kristine H Allin, Mariangela Allocca, Arno R Bourgonje, Johan Burisch, Glen Doherty, Parambir S Dulai, Alaa El-Hussuna, Ravi Misra, Nurulamin Noor, Valérie Pittet, Nick Powell, Iago Rodríguez-Lago, Sophie Restellini

  • May 4, 2025

Related Content

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Renal Conditions Associated with Inflammatory Bowel Disease: Exploring Clinical Links, Shared Mechanisms, and Management Approaches

Exploring Comorbidity Patterns in Inflammatory Bowel Disease: Insights from the All of Us Research Program